Cellosaurus logo
expasy logo

Cellosaurus Rh30 (CVCL_0041)

[Text version]
Cell line name Rh30
Synonyms RH30; RH-30; Rh-30; RH30SJ; SJRH-30; SJRH30; SJ-RH30; SJ-Rh 30; SJRH 30; SJCRH30; RC13; RMS-13; RMS 13; RMS13
Accession CVCL_0041
Secondary accession CVCL_1696; CVCL_UF98
Resource Identification Initiative To cite this cell line use: Rh30 (RRID:CVCL_0041)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Population: Caucasian.
Doubling time: 37 hours (PubMed=20922763); 35.5 +- 3.6 hours (PubMed=35760101); ~35 hours (DSMZ=ACC-489); 35 hours (COG).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Cell surface proteome.
Omics: Exosome proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
Sequence variations
  • Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=8275086; PubMed=17471488; PubMed=23578105; PubMed=25485619; PubMed=25806826).
  • Mutation; HGNC; 9864; RARA; Simple; p.Pro9Leu (c.26C>T); Zygosity=Heterozygous (Cosmic-CLP=909716; DepMap=ACH-000833).
  • Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Heterozygous (Cosmic-CLP=909716; DepMap=ACH-000833).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=9802058; PubMed=19147553; PubMed=25749379; Cosmic-CLP=909716; DepMap=ACH-000833).
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (Cosmic-CLP=909716; DepMap=ACH-000833).
HLA typing Source: PubMed=26589293
Class I
HLA-AA*11:17,24:08
HLA-BB*35:01,35:01
HLA-CC*18:01,18:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African2.64
Native American0.36
East Asian, North1.57
East Asian, South0.14
South Asian4.15
European, North49.28
European, South41.87
Disease Alveolar rhabdomyosarcoma (NCIt: C3749)
Alveolar rhabdomyosarcoma (ORDO: Orphanet_99756)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_RR39 (Rh30rVCR10)CVCL_C1D0 (SJCRH30 POLG Y955C)
Sex of cell Male
Age at sampling 17Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-2061; COG; Cosmic-CLP=909716; DepMap=ACH-000833; DSMZ=ACC-489; PubMed=20922763; PubMed=21948088; PubMed=25877200; Technion Genomics Center

Markers:
AmelogeninX (COG)
X,Y (ATCC=CRL-2061; Cosmic-CLP=909716; DepMap=ACH-000833; DSMZ=ACC-489; PubMed=20922763; PubMed=21948088; PubMed=25877200; Technion Genomics Center)
CSF1PO10,11
D1S165612,16
D2S44111,14
D2S133817,20
D3S135815
D5S81812,13 (ATCC=CRL-2061; COG; Cosmic-CLP=909716; DepMap=ACH-000833; PubMed=20922763; PubMed=21948088; PubMed=25877200; Technion Genomics Center)
12,13,14 (DSMZ=ACC-489)
D7S82010
D8S117912,15
D10S124812
D12S39120
D13S31710,11 (PubMed=21948088)
11 (ATCC=CRL-2061; COG; DepMap=ACH-000833; DSMZ=ACC-489; PubMed=20922763; PubMed=25877200; Technion Genomics Center)
D16S53912
D18S5115,16
D19S43314,15.2 (ATCC=CRL-2061; COG; PubMed=20922763; Technion Genomics Center)
14,16 (DSMZ=ACC-489)
D21S1129,31.2 (ATCC=CRL-2061; COG; DepMap=ACH-000833; DSMZ=ACC-489; PubMed=20922763; Technion Genomics Center)
31.2 (PubMed=25877200)
D22S104516,17
FGA22
Penta D11 (PubMed=25877200)
11,12 (ATCC=CRL-2061; DepMap=ACH-000833; DSMZ=ACC-489; Technion Genomics Center)
Penta E7 (PubMed=25877200)
7,17 (ATCC=CRL-2061; DepMap=ACH-000833; DSMZ=ACC-489; Technion Genomics Center)
TH019,9.3
TPOX8,11 (ATCC=CRL-2061; COG; Cosmic-CLP=909716; DepMap=ACH-000833; DSMZ=ACC-489; PubMed=20922763; PubMed=21948088; Technion Genomics Center)
11 (PubMed=25877200)
vWA17,18

Run an STR similarity search on this cell line
Web pages https://www.cccells.org/PDF_Files/Rhabdomyosarcoma/Rh30%20Cell%20Line%20Data%20Sheet.pdf
http://www.cccells.org/cellreqs-ncipptp.php
https://www.proteinatlas.org/learn/cellines
http://www.pptpinvitro.org/cell_lines_panel.php
https://tcpaportal.org/mclp/
Publications

PubMed=3691179; DOI=10.1159/000132446
Douglass E.C., Valentine M., Etcubanas E., Parham D.M., Webber B.L., Houghton P.J., Houghton J.A., Green A.A.
A specific chromosomal abnormality in rhabdomyosarcoma.
Cytogenet. Cell Genet. 45:148-155(1987)

PubMed=2766305
Roberts W.M., Douglass E.C., Peiper S.C., Houghton P.J., Look A.T.
Amplification of the gli gene in childhood sarcomas.
Cancer Res. 49:5407-5413(1989)

PubMed=8275086; DOI=10.1038/ng1193-230
Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher F.J. 3rd, Emanuel B.S., Rovera G., Barr F.G.
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.
Nat. Genet. 5:230-235(1993)

PubMed=8383879; DOI=10.1126/science.8383879
Tapscott S.J., Thayer M.J., Weintraub H.M.
Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis.
Science 259:1450-1453(1993)

PubMed=7536457; DOI=10.1002/gcc.2870120305
Biegel J.A., Nycum L.M., Valentine V.A., Barr F.G., Shapiro D.N.
Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization.
Genes Chromosomes Cancer 12:186-192(1995)

PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X
Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.-L., Picci P., Bertoni F., Baldini N.
Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.
Hum. Pathol. 27:408-416(1996)

PubMed=9802058
McPake C.R., Tillman D.M., Poquette C.A., George E.O., Houghton J.A., Harris L.C.
Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status.
Oncol. Res. 10:235-244(1998)

PubMed=11051265
Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A.
Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.
Clin. Cancer Res. 6:4119-4127(2000)

PubMed=17354236; DOI=10.1002/ijc.22643
Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G., Myklebost O.
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Int. J. Cancer 121:199-205(2007)

PubMed=17471488; DOI=10.1002/path.2170
Lae M., Ahn E.H., Mercado-Celis G.E., Chuai S., Edgar M., Pawel B.R., Olshen A.B., Barr F.G., Ladanyi M.
Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
J. Pathol. 212:143-151(2007)

PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856
Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K., Fehse B., Kammerer B., Doerr H.-W., Cinatl J. Jr.
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Cancer Res. 69:416-421(2009)

PubMed=19235922; DOI=10.1002/gcc.20655
Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C., Koster J., Summersgill B.M., Messahel B., Versteeg R., Pritchard-Jones K., Kool M., Shipley J.M.
Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
Genes Chromosomes Cancer 48:455-467(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20922763; DOI=10.1002/pbc.22801; PMCID=PMC3005554
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=21948088; DOI=10.1158/1078-0432.CCR-11-1004; PMCID=PMC3241994
Belyea B.C., Naini S., Bentley R.C., Linardic C.M.
Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Clin. Cancer Res. 17:7324-7336(2011)

PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056; PMCID=PMC3271129
Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A., Borsu L., Barr F.G., Ladanyi M.
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Clin. Cancer Res. 18:748-757(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23578105; DOI=10.1111/cas.12173; PMCID=PMC7657110
Nishimura R., Takita J., Sato-Otsubo A., Kato M., Koh K., Hanada R., Tanaka Y., Kato K., Maeda D., Fukayama M., Sanada M., Hayashi Y., Ogawa S.
Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
Cancer Sci. 104:856-864(2013)

PubMed=23828214; DOI=10.3892/or.2013.2588
Yamamoto Y., Fukuda K., Fuchimoto Y., Matsuzaki Y., Saikawa Y., Kitagawa Y., Morikawa Y., Kuroda T.
Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro.
Oncol. Rep. 30:1081-1086(2013)

PubMed=23882450; DOI=10.3389/fonc.2013.00183; PMCID=PMC3713458
Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183.1-183.12(2013)

PubMed=23665679; DOI=10.1038/onc.2013.129
Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25749379; DOI=10.18632/oncotarget.2889; PMCID=PMC4627332
Michaelis M., Rothweiler F., Loschmann N., Sharifi M., Ghafourian T., Cinatl J. Jr.
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.
Oncotarget 6:17605-17620(2015)

PubMed=25806826; DOI=10.1371/journal.pone.0121474; PMCID=PMC4373809
Schmitt-Ney M., Camussi G.
The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-beta pathway.
PLoS ONE 10:E0121474-E0121474(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31448612; DOI=10.1021/acs.jproteome.9b00157
Rammal G., Fahs A., Kobeissy F., Mechref Y., Zhao J.-F., Zhu R., Diab-Assaf M., Saab R., Ghayad S.E.
Proteomic profiling of rhabdomyosarcoma-derived exosomes yield insights into their functional role in paracrine signaling.
J. Proteome Res. 18:3567-3579(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32758582; DOI=10.1016/j.gene.2020.145025
Batchu S., Kellish A.S., Hakim A.A.
Assessing alveolar rhabdomyosarcoma cell lines as tumor models by comparison of mRNA expression profiles.
Gene 760:145025.1-145025.5(2020)

PubMed=35760101; DOI=10.1016/j.jbc.2022.102196; PMCID=PMC9307957
Rahman M.M., Young C.K.J., Goffart S., Pohjoismaki J.L.O., Young M.J.
Heterozygous p.Y955C mutation in DNA polymerase gamma leads to alterations in bioenergetics, complex I subunit expression, and mtDNA replication.
J. Biol. Chem. 298:102196.1-102196.29(2022)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

PubMed=36768928; DOI=10.3390/ijms24032601; PMCID=PMC9917031
Timpanaro A., Piccand C., Uldry A.-C., Bode P.-K., Dzhumashev D., Sala R., Heller M., Rossler J., Bernasconi M.
Surfaceome profiling of cell lines and patient-derived xenografts confirm FGFR4, NCAM1, CD276, and highlight AGRL2, JAM3, and L1CAM as surface targets for rhabdomyosarcoma.
Int. J. Mol. Sci. 24:2601.1-2601.28(2023)

Cross-references
Cell line collections (Providers) ATCC; CRL-2061
BCRC; 60420
BCRJ; 0344
DSMZ; ACC-489
Cell line databases/resources CLO; CLO_0009030
CLO; CLO_0037074
CLO; CLO_0037076
cancercelllines; CVCL_0041
Cell_Model_Passport; SIDM01095
Cosmic-CLP; 909716
DepMap; ACH-000833
DepMap; ACH-001189
DepMap; ACH-001741 - Discontinued
DSMZCellDive; ACC-489
IGRhCellID; SJRH30
LINCS_HMS; 50041
LINCS_LDP; LCL-1408
LINCS_LDP; LCL-1414
Anatomy/cell type resources BTO; BTO:0005379
Biological sample resources 4DN; 4DNSR3QR626J
BioSample; SAMN03471424
BioSample; SAMN03473112
BioSample; SAMN03473563
BioSample; SAMN10987899
BioSample; SAMN10988045
ENCODE; ENCBS504BIZ
ENCODE; ENCBS516AAA
ENCODE; ENCBS517AAA
CRISP screens repositories BioGRID_ORCS_Cell_line; 479
Chemistry resources ChEMBL-Cells; CHEMBL3308364
ChEMBL-Targets; CHEMBL1075575
GDSC; 909716
PharmacoDB; RH30_1312_2019
PubChem_Cell_line; CVCL_0041
Encyclopedic resources Wikidata; Q54950341
Experimental variables resources EFO; EFO_0002329
EFO; EFO_0005722
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM186449
GEO; GSM186450
GEO; GSM186451
GEO; GSM186452
GEO; GSM219757
GEO; GSM887573
GEO; GSM888620
GEO; GSM888656
GEO; GSM1670425
GEO; GSM1676311
GEO; GSM1676315
GEO; GSM1701645
GEO; GSM1701649
Polymorphism and mutation databases Cosmic; 687957
Cosmic; 687964
Cosmic; 801758
Cosmic; 909716
Cosmic; 1037297
Cosmic; 1048110
Cosmic; 1097749
Cosmic; 1082515
Cosmic; 1104562
Cosmic; 1108737
Cosmic; 1309335
Cosmic; 1509197
Cosmic; 1620038
Cosmic; 1718361
Cosmic; 2355914
Cosmic; 2820087
IARC_TP53; 356
IARC_TP53; 24983
IARC_TP53; 27704
LiGeA; CCLE_004
Progenetix; CVCL_0041
Proteomic databases PRIDE; PXD007755
PRIDE; PXD030304
PRIDE; PXD039480
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number45